Angiotensin-II Receptor Antagonist Alleviates Non-alcoholic Fatty Liver in KKAy Obese Mice with Type 2 Diabetes

Author： Yu F   Takahashi T   Moriya J   Kawaura K   Yamakawa J   Kusaka K   Itoh T   Sumino H   Morimoto S   Kanda T  

Publisher： Field House Publishing

ISSN： 0300-0605

Source： The Journal of International Medical Research, Vol.34, Iss.3, 2006-05, pp. : 297-302

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Role of Oral Antidiabetic Agents and Incretin Mimetics in Type 2 Diabetic Patients with Non-Alcoholic Fatty Liver Disease

By  

Current Pharmaceutical Design, Vol. 20, Iss. 22, 2014-05 ,pp. : 3705-3715

Bentham Science Publishers

Access to resources Recommend Favorite

Effects of Olmesartan Medoxomil, an Angiotensin II Type 1 Receptor Antagonist, on Plasma Concentration of B-Type Natriuretic Peptide, in Hypertensive Patients with Type 2 Diabetes Mellitus: A Preliminary, Observational, Open-Label Study

By Kawai Toshihide   Takei Izumi   Shimada Akira  

Clinical Drug Investigation, Vol. 31, Iss. 4, 2011-04 ,pp. : 237-245

Adis International

Access to resources Recommend Favorite

Emerging drugs for non-alcoholic fatty liver disease

By Federico Alessandro   Niosi Marco   Vecchio Blanco Camillo Del   Loguercio Carmela  

Expert Opinion on Emerging Drugs, Vol. 13, Iss. 1, 2008-03 ,pp. : 145-158

Informa Healthcare

Access to resources Recommend Favorite

Non-alcoholic fatty liver disease: a massive problem

By Day Christopher P  

Clinical Medicine, Vol. 11, Iss. 2, 2011-04 ,pp. : 176-178

Royal College Of Physicians

Access to resources Recommend Favorite

Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome

By  

Current Pharmaceutical Design, Vol. 13, Iss. 21, 2007-01 ,pp. : 2193-2198

Bentham Science Publishers

Access to resources Recommend Favorite